



ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA
DIPARTIMENTO DI
SCIENZE MEDICHE E CHIRURGICHE

POLICLINICO DI
SANT'ORSOLA

 **SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA**
Azienda Ospedaliero - Universitaria di Bologna

New Drugs in Hematology

President: Pier Luigi Zinzani

Co-President: Michele Cavo

**Bologna,
Royal Hotel Carlton
January 15-17, 2024**

BOLOGNA

BOLOGNA, ROYAL HOTEL CARLTON

PROGRAM

Auspices

**ALMA MATER STUDIORUM
UNIVERSITÀ DEGLI STUDI DI BOLOGNA**

REGIONE EMILIA-ROMAGNA


**AZIENDA OSPEDALIERO-UNIVERSITARIA
DI BOLOGNA**

**AIL ASSOCIAZIONE ITALIANA CONTRO
LE LEUCEMIE - LINFOMI E MIELOMA**

SEZIONE DI BOLOGNA

SIE - SOCIETÀ ITALIANA DI EMATOLOGIA

**SIES - SOCIETÀ ITALIANA DI EMATOLOGIA
SPERIMENTALE**



Faculty

Haifa K.	Al-Ali	Halle, Germany	Marco	Ladetto	Alessandria, Italy
Othman	Al-Sawaf	Cologne, Germany	Roberto M.	Lemoli	Genova, Italy
Stephen M.	Ansell	Rochester, USA	Mark	Levis	Baltimore, USA
Paul M.	Barr	Rochester, USA	Franco	Locatelli	Rome, Italy
Massimiliano	Bonifacio	Verona, Italy	Maurizio	Martelli	Rome, Italy
Massimo	Breccia	Rome, Italy	Francesca R.	Mauro	Rome, Italy
Jennifer	Brown	Boston, USA	Jean-Marie	Michot	Villejuif, France
Tim H.	Bruemmendorf	Aachen, Germany	Phillipe	Moreau	Nantes, France
Elizabeth L.	Budde	Duarte, USA	Saatva S.	Neelapu	Houston, USA
John C.	Byrd	Cincinnati, USA	Paola	Neri	Calgary, Canada
Carmelo	Carlo-Stella	Rozzano-Mi, Italy	Francesca	Palandri	Bologna, Italy
Fausto	Castagnetti	Bologna, Italy	Cristina	Papayannidis	Bologna, Italy
Michele	Cavo	Bologna, Italy	Andrew B.	Provan	London, UK
Chan	Cheah	Perth, Australia	Alessandro	Rambaldi	Bergamo, Italy
Bruce D.	Cheson	Washington, USA	Delphine	Rea	Paris, France
Marilena	Ciciarello	Bologna, Italy	Andreas	Reiter	Heidelberg, Germany
Paolo	Corradini	Milan, Italy	Katy	Rezvani	Houston, USA
Antonio	Curti	Bologna, Italy	Vincent N.	Ribrag	Villejuif, France
Alexey V.	Danilov	Duarte, USA	Marco	Ruella	Philadelphia, USA
Stéphan	De Botton	Villejuif, France	David A.	Sallman	Tampa, USA
Michael	Dickinson	Melbourne, Australia	Stephen J.	Schuster	Philadelphia, USA
Daan	Dierickx	Leuven, Belgium	Tanya	Siddiqi	Duarte, USA
Johannes A.	Duell	Wuerzburg, Germany	Michele	Spina	Aviano-PN, Italy
Kieron	Dunleavy	Washington, USA	Marion	Subklewe	Munich, Germany
Jonathan	Friedberg	Rochester, USA	Anna	Sureda	Barcelona, Spain
Guillermo	Garcia-Manero	Houston, USA	Alessandra	Tedeschi	Milan, Italy
Heinz	Gisslinger	Wien, Austria	Catherine	Thieblemont	Paris, France
Paola	Guglielmelli	Florence, Italy	Suzanne	Trudel	Toronto, Canada
Mehdi	Hamadani	Milwaukee, USA	Alessandro M.	Vannucchi	Florence, Italy
Steven M.	Horwitz	New York, USA	Adriano	Venditti	Rome, Italy
Swaminathan P.	Iyer	Houston, USA	Nicola	Vianelli	Bologna, Italy
Elias J.	Jabbour	Houston, USA	Michael	Wang	Houston, USA
Ryan W.	Jacobs	Charlotte, USA	Andrew H.	Wei	Melbourne, Australia
Caron A.	Jacobson	Boston, USA	Jasmine	Zain	Duarte, USA
Wojciech	Jurczak	Krakow, Poland	Elena	Zamagni	Bologna, Italy
Won Seog	Kim	Seoul, Korea	Pier Luigi	Zinzani	Bologna, Italy
Shaji	Kumar	Rochester, USA			
Andrew	Kuykendall	Tampa, USA			
Ann S.	La Casce	Boston, USA			

Monday, January 15, 2024

09.00 a.m. *Welcome and introduction*

SESSION I: CAR-T, update clinical trials and RWE

Chairman: P. Corradini

09.15 a.m. HG-BCL - *S.J. Schuster*

09.45 a.m. Follicular lymphoma - *C.A. Jacobson*

10.15 a.m. Mantle cell lymphoma - *M. Wang*

SESSION II: Hodgkin's lymphoma

Chairmen: S.M. Ansell, P.L. Zinzani

10.45 a.m. Frontline advanced stage - *J. Friedberg*

11.00 a.m. 1st relapse - *S.M. Ansell*

11.15 a.m. New agents in R/R patients - *A.S. La Casce*

11.30 a.m. Treatment strategies in elderly patients - *A. Sureda*

11.45 a.m. Primary mediastinal lymphoma - *K. Dunleavy*

12.00 p.m. Grey zone lymphoma - *S.M. Ansell*

12.15 p.m. CAR-T - *F. Locatelli*

Lectures on PROTAC therapies

Chairman: B.D. Cheson

12.50 p.m. NX-2127 - *A.V. Danilov*

01.10 p.m. BGB-16673 - *C. Cheah*

01.30 p.m. **Lunch**

SESSION III: Acute leukemias

Chairmen: A. Curti, A. Venditti

02.30 p.m. Immunotherapy in AML: targeting immunosuppressive microenvironment - *M. Ciciariello*

02.45 p.m. Targeting CD123 in AML and BPDCN - *R.M. Lemoli*

03.00 p.m. Anti-CD47 MoAbs in AML and MDS - *D.A. Sallman*

03.15 p.m. Immune checkpoint inhibitors in AML and MDS - *G. Garcia-Manero*

03.30 p.m. T-cell engagers in AML and ALL - *M. Subklewe*

03.45 p.m. IDH inhibitor: ivo, ena and beyond - *S. De Botton*

04.15 p.m. **Coffee break**

04.30 p.m. BCL2 inhibitors: not only venetoclax - *A.H. Wei*


04.45 p.m. Novel FLT3 inhibitors - *M. Levis*

05.00 p.m. Subcutaneous blinatumomab in adult ALL - *A. Rambaldi*

05.15 p.m. Menin-inhibitors - *C. Papayannidis*

05.30 p.m. Targeting the BCL2/BCLx pathway in T-ALL - *E.J. Jabbour*

05.45 p.m. CAR-T cells for adult ALL and AML - *M. Ruella*



SESSION IV: Classical Ph1-neg myeloproliferative neoplasms

Chairmen: F. Palandri, A.M. Vannucchi

- 08.30 a.m. Cytoreduction in low-risk PV: when, and which drug? - *H. Gisslinger*
- 08.45 a.m. Hydroxyurea, interferons, ruxolitinib or clinical trials: what sequence in polycythemia vera? - *F. Palandri*
- 09.00 a.m. The future of 1st line therapy in myelofibrosis - *A. Kuykendall*
- 09.15 a.m. Second-line therapy of myelofibrosis - *H.K. Al-Ali*
- 09.30 a.m. What is disease modification in myelofibrosis - *A. Reiter*
- 09.45 a.m. MPNs in accelerated/blast phase - *P. Guglielmelli*

SESSION V: Non-Hodgkin's lymphoma (I)

Chairmen: C. Carlo-Stella, M. Ladetto


- 10.00 a.m. Tafasitamab - *J.A. Duell*
- 10.15 a.m. Epcoritamab - *C. Thieblemont*
- 10.30 a.m. Glofitamab - *M. Dickinson*
- 10.45 a.m. Mosunetuzumab - *E.L. Budde*
- 11.00 a.m. Odronextamab - *W.S. Kim*
- 11.15 a.m. TNB-486 - *R.W. Jacobs*
- 11.30 a.m. Polatuzumab vedotin - *B.D. Cheson*
- 11.45 a.m. Loncastuximab tesirine - *M. Hamadani*
- 12.00 p.m. Tazemetostat - *V.N. Ribrag*

- 12.45 p.m. Lunch

SESSION VI: Non-Hodgkin's lymphoma (II)

Chairmen: M. Martelli, M. Spina

- 02.00 p.m. Zilovetamab - *P.M. Barr*
- 02.15 p.m. Linperlisib - *S.P. Iyer*
- 02.30 p.m. Pirtobrutinib - *W. Jurczak*
- 02.45 p.m. Zanubrutinib - *P.L. Zinzani*
- 03.00 p.m. Golidocitinib - *W.S. Kim*
- 03.15 p.m. Valemestostat - *S.M. Horwitz*
- 03.30 p.m. Iberdomide - *C. Thieblemont*
- 03.45 p.m. Golcadomide - *J.M. Michot*
- 04.00 p.m. CDK9 inhibitors - *J. Zain*



**SESSION VII: Non-Hodgkin's lymphoma
- The next steps of CAR-T**

Chairman: *S.J. Schuster*

- 04.30 p.m. New generations of CAR-T - *S.J. Schuster*
- 04.45 p.m. Allo CAR-T - *S.S. Neelapu*
- 05.00 p.m. CAR-NK cells - *K. Rezvani*
- 05.15 p.m. Gamma delta CART19 - *S.S. Neelapu*

SESSION VIII: Chronic myeloid leukemia

Chairmen: *M. Breccia, F. Castagnetti*

- 05.45 p.m. Status of the art of treatment - *M. Breccia*
- 06.00 p.m. Asciminib - *D. Rea*
- 06.15 p.m. Ponatinib - *F. Castagnetti*
- 06.30 p.m. Second generation TKIs - *T.H. Bruemmendorf*
- 06.45 p.m. New agents - *M. Bonifacio*

Lectures


Chairman: *N. Vianelli*

- 08.30 a.m. New agents in the treatment of immune thrombocytopenia - *A.B. Provan*
- 09.00 a.m. Improving outcomes of EBV+ PTLD with T-cell immunotherapy - *D. Dierickx*

SESSION IX: Chronic lymphocitic leukemia

Chairmen: *F.R. Mauro, A. Tedeschi*

- 09.30 a.m. Ibrutinib - *W. Jurczak*
- 09.45 a.m. Venetoclax - *O. Al-Sawaf*
- 10.00 a.m. Acalabrutinib - *J.C. Byrd*
- 10.15 a.m. Zanubrutinib - *J. Brown*
- 10.30 a.m. Pirtobrutinib - *W. Jurczak*
- 10.45 a.m. Nemtabrutinib - *J.C. Byrd*
- 11.00 a.m. BGB-11417 - *C. Cheah*
- 11.15 a.m. CAR-T - *T. Siddiqi*




Wednesday, January 17, 2024

SESSION X: Multiple myeloma

Chairman: M. Cavo

- 11.45 a.m.** 2nd generation anti-BCMA
and -GPRC5D autologous CAR-T - *E. Zamagni*
- 12.00 p.m.** Antibody drug conjugates - *S. Trudel*
- 12.15 p.m.** Bispecific antibodies - *P. Moreau*
- 12.30 p.m.** Resistance mechanisms - *P. Neri*
- 12.45 p.m.** T-cell directing therapies sequencing - *S. Kumar*
- 01.15 p.m.** **Arrivederci**

GENERAL INFORMATION



GENERAL INFORMATION

MEETING VENUE

Royal Hotel Carlton

Via Montebello, 8 - 40121 Bologna, Italy

Phone +39 051 249361

www.royalhotelcarltonbologna.com

OFFICIAL LANGUAGE

English

REGISTRATION

Registration is available at www.ercongressi.it - section "I nostri congressi/anno 2024"

The registration includes conference kit, participation in the scientific sessions, attendance certificate, coffee break, lunch, slides of the meeting.

BADGE AND CERTIFICATE OF ATTENDANCE

All registered participants, speakers and sponsors will be given a badge which they must wear to be admitted to the scientific sessions. A certificate will be given to all participants at the end of the meeting.

ITALIAN CME CREDITS

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi SRL: ID 828-401090.
- No. **6 CME** credits for Physicians (disciplines: Allergology and Clinical Immunology, Dermatology and Venereology, Hematology, Oncology, Pathological Anatomy, Clinical Biochemistry, Clinical Pathology), Biologists and Chemists.
- Educational objective: "linee guida-protocolli-procedure".

EUROPEAN CME CREDITS

The program of the "New Drugs in Hematology" has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. 21 CME credits for Physicians, Biologists and Chemists. To request credits, please fill out the form and return it to the registration desk at the end of the meeting. We remind you that it is necessary to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: <http://ebah.org>.

CHANGES

Parts of the program may be changed without notice.



New Drugs in Hematology

Scientific Secretariat

Pier Luigi Zinzani

Istituto di Ematologia

“Lorenzo e Ariosto Seràgnoli”

Via Massarenti, 9 - 40138 Bologna, Italy

Organizing Secretariat

Studio E.R. Congressi

Via De' Poeti, 1/7 - 40124 Bologna, Italy

Phone +39 051 4210559 - Fax +39 051 4210174

e-mail: ercongressi@ercongressi.it

www.ercongressi.it

